European journal of medicinal chemistryMay 19, 2023

Summary of FDA-Approved Fluorinated Drugs in the U.S. from 2018 to 2022

Alzheimers & Treatments Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 31, 2026

Abstract

The U.S. Food and Drug Administration approved a total of fifty-eight fluorinated drugs from 2018 to 2022.

Thirty of the approved drugs are intended for the treatment of various types of cancers.
Twelve drugs are aimed at addressing infectious diseases.
Eleven fluorinated drugs are developed for central nervous system disorders.
Six additional drugs are categorized for other types of diseases.
The review includes details on trade names, approval dates, active ingredients, developers, indications, and drug mechanisms.

Simplified

The objective of this review is to provide an update on the fluorine-containing drugs approved by U.S. Food and Drug Administration in the span of past five years (2018-2022). The agency accepted a total of fifty-eight fluorinated entities to diagnose, mitigate and treat a plethora of diseases. Among them, thirty drugs are for therapy of various types of cancers, twelve for infectious diseases, eleven for CNS disorders, and six for some other diseases. These are categorized and briefly discussed based on their therapeutic areas. In addition, this review gives a glimpse about their trade name, date of approval, active ingredients, company developers, indications, and drug mechanisms. We anticipate that this review may inspire the drug discovery and medicinal chemistry community in both industrial and academic settings to explore the fluorinated molecules leading to the discovery of new drugs in the near future.

Full Text

Full text is available at the source.

View Full Text ↗

Summary of FDA-Approved Fluorinated Drugs in the U.S. from 2018 to 2022

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief